Analyst Reco. Amylyx Pharmaceuticals, Inc.

Equities

AMLX

US03237H1014

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.76 ^USD	-1.12%		-5.88%	-88.04%

Apr. 11	Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating	MT
Apr. 10	Transcript : Amylyx Pharmaceuticals, Inc. - Special Call

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating	Apr. 11	MT
Deutsche Bank Cuts Amylyx Pharmaceuticals' Price Target to $4 From $8, Maintains Buy Rating	Apr. 05	MT
Mizuho Downgrades Amylyx Pharmaceuticals to Neutral From Buy After Negative Results From Phase 3 PHEONIX Study, Adjusts PT to $4 From $32	Mar. 18	MT
H.C. Wainwright Adjusts Price Target on Amylyx Pharmaceuticals to $8 From $42, Maintains Buy Rating	Mar. 12	MT
Deutsche Bank Cuts Amylyx Pharmaceuticals' Price Target to $8 From $36, Maintains Buy Rating	Mar. 11	MT
Goldman Sachs Downgrades Amylyx Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $4 From $40	Mar. 11	MT
Leerink Partners Downgrades Amylyx Pharmaceuticals to Market Perform From Outperform	Mar. 11	MT
Baird Downgrades Amylyx Pharmaceuticals to Neutral From Outperform, Cuts Price Target to $4 From $37	Mar. 11	MT
Mizuho Securities Ups Price Target on Amylyx Pharmaceuticals to $32 From $27 on New Revenue Contributions by PSP, Wolfram Therapies, Keeps Buy Rating	Mar. 08	MT
Baird Starts Amylyx Pharmaceuticals With Outperform Rating, $37 Price Target	Jan. 03	MT
Mizuho Slashes Price Target on Amylyx Pharmaceuticals to $27 From $46, Keeps Buy Rating	Dec. 21	MT
Deutsche Bank Initiates Coverage on Amylyx Pharmaceuticals With Buy Rating, $36 Price Target	Dec. 12	MT
Goldman Sachs Adjusts Price Target on Amylyx Pharmaceuticals to $40 From $46, Maintains Buy Rating	Nov. 10	MT
HC Wainwright Adjusts Price Target on Amylyx Pharmaceuticals to $42 From $50, Keeps Buy Rating	Nov. 10	MT
Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $46 From $48, Keeps Buy Rating	23-10-19	MT
Goldman Sachs Upgrades Amylyx Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $49 From $45	23-07-24	MT
Mizuho Securities Cuts Amylyx Pharmaceuticals' Price Target to $50 From $52, Buy Rating Kept	23-05-12	MT
Citigroup Trims Amylyx Pharmaceuticals' Price Target to $53 From $54, Buy Rating Kept	23-05-12	MT
Goldman Sachs Cuts Amylyx Pharmaceuticals' Price Target to $45 From $47, Neutral Rating Kept	23-05-12	MT
Mizuho Initiates Amylyx Pharmaceuticals at Buy With $52 Price Target	23-03-31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Amylyx Pharmaceuticals, Inc.

Equities

AMLX

US03237H1014

Analyst Reco.

Filters